T

Tianda Pharmaceuticals Ltd
HKEX:455

Watchlist Manager
Tianda Pharmaceuticals Ltd
HKEX:455
Watchlist
Price: 0.109 HKD
Market Cap: HK$234.4m

Relative Value

The Relative Value of one Tianda Pharmaceuticals Ltd stock under the Base Case scenario is 0.156 HKD. Compared to the current market price of 0.109 HKD, Tianda Pharmaceuticals Ltd is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
0.156 HKD
Undervaluation 30%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Tianda Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Tianda Pharmaceuticals Ltd
HKEX:455
234.4m HKD 0.8 -3.5 -9.9 -3.3
US
Eli Lilly and Co
NYSE:LLY
954.9B USD 16.1 51.8 34.8 37.3
US
Johnson & Johnson
NYSE:JNJ
546.2B USD 5.8 20.4 14.2 17.4
CH
Roche Holding AG
SIX:ROG
268.4B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP 4.9 30.3 19.7 28.9
CH
Novartis AG
SIX:NOVN
219B CHF 5 19.3 15.5 20
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
US
Merck & Co Inc
NYSE:MRK
265.4B USD 4.1 13.9 9.9 11.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.6B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
94.4B EUR 1.4 6.9 6.3 6.3
P/E Multiple
Earnings Growth PEG
HK
T
Tianda Pharmaceuticals Ltd
HKEX:455
Average P/E: 22.5
Negative Multiple: -3.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.8
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.3
38%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
2%
8.2
US
Merck & Co Inc
NYSE:MRK
13.9
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
6.9
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
T
Tianda Pharmaceuticals Ltd
HKEX:455
Average EV/EBITDA: 47.6
Negative Multiple: -9.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.3
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
T
Tianda Pharmaceuticals Ltd
HKEX:455
Average EV/EBIT: 102.4
Negative Multiple: -3.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.4
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
CH
Novartis AG
SIX:NOVN
20
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.3
15%
0.4